Peter Charles Astles

Title: Peter Charles Astles: Innovator in Neurotransmission Modulation

Introduction

Peter Charles Astles is a notable inventor based in Basingstoke, GB. He has made significant contributions to the field of neurotransmission modulation, holding two patents that focus on the modulation of acetylcholine receptors. His work is particularly relevant for the treatment of dysfunctions in the central and autonomic nervous systems.

Latest Patents

Astles' latest patents include "Aza-cyclic compounds as modulators of acetylcholine receptors" and "Modulators of acetylcholine receptors." The first patent discloses compounds that comprise an aza-cyclic portion and an aromatic portion linked via a sulphur atom. These compounds are selective modulators of the beta 4 subtype nicotinic acetylcholine receptors, which are useful for treating various dysfunctions of the nervous system. The second patent relates to thio-bridged aryl compounds that promote the release of neurotransmitters such as acetylcholine, dopamine, and norepinephrine. These compounds also aim to modulate acetylcholine receptors and are beneficial for addressing dysfunctions in the nervous systems.

Career Highlights

Throughout his career, Peter Charles Astles has worked with prominent companies, including Merck & Company, Inc. and Merck + Co., Inc. His experience in these organizations has contributed to his expertise in the field of pharmaceutical innovations.

Collaborations

Astles has collaborated with notable coworkers such as Stephen Richard Baker and Jean Michel Vernier. These collaborations have likely enriched his research and development efforts in neurotransmission modulation.

Conclusion

Peter Charles Astles is a distinguished inventor whose work in neurotransmission modulation has the potential to impact the treatment of nervous system dysfunctions significantly. His patents reflect a commitment to advancing medical science and improving patient outcomes.